Development Of Companion Diagnostics For Pralsetinib In China
29/06/2020 02:02
June 28 (Reuters) - Burning Rock Biotech Ltd BNR.O :
* BURNING ROCK AND CSTONE PHARMACEUTICALS REACHED A STRATEGIC COLLABORATION ON
CO-DEVELOPMENT OF
COMPANION DIAGNOSTICS FOR PRALSETINIB IN CHINA
Source text for Eikon: ID:nGNXvYMYY
Further company coverage: BNR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Burning Rock Biotech
See all newsBurning Rock Biotech's Q2 revenue falls, net loss widens on central laboratory weakness
China's Burning Rock Biotech Q1 revenue falls on lower test volumes
China's Burning Rock Biotech Q4 net loss narrows as costs fall
Cancer diagnostics firm Burning Rock Biotech's Q3 revenue rises on pharma R&D growth
Brief: Burning Rock's Oncoguide™ Oncoscreen™ Plus CDX System Now Approved In Japan As A Companion Diagnostic For Capivasertib In Breast Cancer